Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284206 · ClinicalTrials.gov registry record · Phase 2
A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence
A Phase 2 study of Methamphetamine-dependence, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00284206: Completed Phase 2 study of Methamphetamine-dependence, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT00284206 is a Phase 2 study of Methamphetamine-dependence that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 20 participants, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00284206, a Phase 2 study of Methamphetamine-dependence, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective of the Project. -Methamphetamine (MA) use is growing to epidemic proportions and existing treatments for MA dependence demonstrate sub-optimal efficacy. Research implicates heavy use of MA as at least a contributing agent to a variety of neuropsychiatric impairments including psychosis, mood disturbance, anxiety, cognitive deficits, and motor dysfunction. Initial study by this investigator suggests that agents like risperidone may also be beneficial to MA dependent individuals by decreasing MA use and improving cognitive function in early abstinence. Long-acting injectable risperidone may prove more efficacious given its receptor binding characteristics and potential to increase medication adherence. The study objective is to determine the safety and efficacy of treating MA dependence and the associated cognitive and psychiatric symptomatology with long-acting injectable risperidone.
Conditions Studied
Interventions
- DRUG long-acting injectable risperidone
Study Locations (1)
Washington
- VA Puget Sound Health Care System, Addictions Treatment Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00284206 record still lists
NCT00284206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Methamphetamine-dependence appearing as the primary indexed condition, and to 1 intervention - of which long-acting injectable risperidone is the first listed.
NCT00284206 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00284206 about?
NCT00284206 is a clinical study titled "A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence". Objective of the Project. -Methamphetamine (MA) use is growing to epidemic proportions and existing treatments for MA dependence demonstrate sub-optimal efficacy. Research implicates heavy use of MA as at least a contributing agent to a variety of neuropsychiatric impairments including psychosis, m...
What is the current status of trial NCT00284206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-01. Estimated completion is 2007-08.
What conditions does trial NCT00284206 study?
This clinical trial studies the following conditions: Methamphetamine-dependence.
What interventions are being tested in trial NCT00284206?
The interventions under investigation include: long-acting injectable risperidone (DRUG).
Who is sponsoring clinical trial NCT00284206?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00284206 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00284206's enrollment target sits among peer trials
20 14th of 18 higher than 4 of 18 other Methamphetamine-dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine-dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
-
Study of Medical Treatment for Methamphetamine Addiction
COMPLETED · Phase 2
-
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
COMPLETED · Phase 2
-
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
COMPLETED · Phase 2
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia